Dutasteride

Posted on February 11th, 2013 by

Class: Hormonal therapy

Generic Name: Dutasteride

Trade Names: Avodart®

How is this drug used? Avodart is used alone or in combination with another drug—tamsulosin—to treat symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. Avodart is used to improve symptoms, reduce the risk of sudden inability to pass urine, and reduce the need for surgery related to BPH. Avodart is not approved for the prevention of prostate cancer.

What is the mechanism of action? Avodart lowers the levels of a hormone called dihydrotestosterone (DHT). DHT plays a role in prostate growth. Lowering DHT levels can cause the prostate to shrink.

How is Avodart given (administered)? Avodart is taken orally (by mouth).

How are patients monitored? Patients will usually have scheduled meetings with their healthcare provider while they are being treated with Avodart. Patients may also undergo physical examinations, blood tests, or other measures to assess side effects and response to therapy.

What are the most common side effects of treatment with Avodart?

  • Trouble getting or keeping an erection
  • Decrease in sex drive
  • Problems with ejaculation
  • Painful or enlarged breasts (report breast lumps or nipple discharge to your physician)

What are some of the other potential side effects of Avodart?

  • An increased risk of a more serious form of prostate cancer
  • Allergic reactions

This is not a complete list of side effects. Some patients may experience other side effects that are not listed here. Patients may wish to discuss with their physician the other less common side effects of this drug, some of which may be serious.

Some side effects may require medical attention. Other side effects do not require medical attention and may go away during treatment. Patients should check with their physician about any side effects that continue or are bothersome.

What can patients do to help alleviate or prevent discomfort and side effects?

  • Pay careful attention to the physician’s instructions, and discuss side effects with your physician.

Are there any special precautions patients should be aware of before starting treatment?

  • Patients should inform their physician about all medical conditions, including allergies and liver problems.
  • Patients should inform their physician of any other medication or supplement they are taking (whether prescription or over-the-counter).
  • Avodart lowers prostate-specific antigen (PSA) levels. Any increase in PSA during treatment with Avodart may be a sign of prostate cancer and should be further evaluated, even if PSA is at a level that would be considered normal among men who are not taking Avodart.
  • Avodart is not for use in women. Pregnant women should not touch Avodart capsules. Avodart can harm an unborn child.
  • Patients should not donate blood while taking Avodart or for six months after they have stopped taking Avodart.

When should patients notify their physician?

Tell your doctor if you experience any side effects that bother you or don’t go away. Also tell your doctor if you have signs of an allergic reaction (such as swelling of the face, tongue, or throat, or skin reactions) or breast changes such as lumps or nipple discharge.

What is a package insert?

A package insert is required by the FDA and contains a summary of the essential scientific information needed for the safe and effective use of the drug for healthcare providers and consumers. A package insert typically includes information regarding specific indications, administration schedules, dosing, side effects, contraindications, results from some clinical trials, chemical structure, pharmacokinetics and metabolism of the specific drug. By carefully reviewing the package insert, you will get the most complete and current information about how to safely use this drug. If you do not have the package insert for the drug you are using, your pharmacist or physician may be able to provide you with a copy.

Copyright © 2016 CancerConnect Last updated 02/13.

Important Limitations of Use

The information provided above on the drug you have selected is provided for your information only and is not a substitute for consultation with an appropriate medical doctor. We are providing this information solely as a courtesy and, as such, it is in no way a recommendation as to the safety, efficacy or appropriateness of any particular drug, regimen, dosing schedule for any particular cancer, condition or patient nor is it in any way to be considered medical advice. Patients should discuss the appropriateness of a particular drug or chemotherapy regimen with their physician.

As with any printed reference, the use of particular drugs, regimens and drug dosages may become out-of-date over time, since new information may have been published and become generally accepted after the latest update to this printed information. Please keep in mind that health care professionals are fully responsible for practicing within current standards, avoiding use of outdated regimens, employing good clinical judgment in selecting drugs and/or regimens, in calculating doses for individual patients, and verifying all dosage calculations.

DISCLAIMER OF WARRANTIES

CANCERCONNECT.COM SPECIFICALLY DISCLAIMS AND EXCLUDES ALL EXPRESSED OR IMPLIED WARRANTIES, INCLUDING ANY IMPLIED WARRANTIES AS TO QUALITY, ACCURACY (INCLUDING TYPOGRAPHICAL ERRORS), MERCHANTABILITY, OR FITNESS FOR ANY PARTICULAR PURPOSE OF THE INFORMATION CONTAINED HEREIN. CANCERCONNECT.COM DISCLAIMS ALL LIABILITY OR DAMAGES ARISING FROM ANY USE OF THE INFORMATION.

The prescribing physician is solely responsible for making all decisions relating to appropriate patient care including, but not limited to, drugs, regimens, dose, schedule, and any supportive care.

Tags: D, Drug Dictionary, Hormonal Therapy

You must be logged-in to the site to post a comment.